IGF-Binding Proteins: Why Do They Exist and Why Are There So Many?

Allard JB, Duan C. · 2018

Read IGF-Binding Proteins: Why Do They Exist and Why Are There So Many? by Allard JB, Duan C. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5900387.txt.

Introduction

Allard and Duan ask why so many IGF-binding proteins exist. Their review appeared in Frontiers in Endocrinology. Six distinct types bind insulin-like growth factors in blood and tissues. They bind as tightly as the main IGF receptor does. That puts them in control of IGF signals. Each type has its own form and pattern.

Binding extends how long IGF lasts in the blood. It also blocks stray binding to the insulin receptor. Some types act on their own, apart from IGF. Loss studies have shown oddly little effect so far. The authors argue the set fine-tunes signals under stress. Normal lab tests may miss those special roles.

Catalog record

CREATORAllard JB, Duan C.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE61 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5900387

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

IGF-Binding Proteins: Why Do They Exist and Why Are There So Many? By John B. Allard, Cunming Duan Published in: Frontiers in Endocrinology DOI: 10.3389/fendo.2018.00117 ABSTRACT Insulin-like growth factors (IGFs) are key growth-promoting peptides that act as both endocrine hormones and autocrine/paracrine growth factors. In the bloodstream and in local tissues, most IGF molecules are bound by one of the members of the IGF-binding protein (IGFBP) family, of which six distinct types exist. These proteins bind to IGF with an equal or greater affinity than the IGF1 receptor and are thus in a key position to regulate IGF signaling globally and locally. Binding to an IGFBP increases the half-life of IGF in the circulation and blocks its potential binding to the insulin receptor. In addition to these classical roles, IGFBPs have been shown to modulate IGF signaling locally under various conditions. Although members of the IGFBP family share significant sequence homology, they each have unique structural features and play distinct roles. These IGFBP genes also have different modes of regulation and distinct expression patterns. Some IGFBPs have been found to bind to their own receptors or to translocate into the interior compartments of cells where they may execute IGF-independent actions. In spite of this functional and regulatory diversity, it has been puzzling that loss-of-function studies have yielded relatively little information about the physiological functions of IGFBPs. In this review, we suggest that evolution has tended to retain an array of IGFBPs in order to facilitate fine-tuning of IGF signaling. We explore the emerging explanation that many IGFBP functions have evolved to allow the targeted adjustment of IGF signaling under stressful or irregular conditions, which would likely not be revealed in a standard laboratory setting. INTRODUCTION The insulin and insulin-like growth factor (IGF) signaling pathway is highly conserved among the metazoans. Many invertebrates have large numbers of insulin-like peptides (ILPs); for instance, the Caenorhabditis elegans genome contains around 40 (http://wormbase.org), and the Drosophila melanogaster genome contains 8 (http://flybase.org). In vertebrates, the ancestral insulin-like gene has diverged into insulin, IGFs-1 and -2, and several ILPs including relaxin and relaxin-like peptide (1). Insulin primarily acts in an endocrine fashion to regulate metabolism, whereas IGFs have a variety of roles as endocrine, paracrine and autocrine factors that promote cell growth, proliferation, differentiation, survival, etc. Both IGF-1 and IGF-2 bind to the IGF-1 receptor (IGF1R), which is expressed in almost all cells, with hepatocytes being an important exception in mammals. The liver secretes IGF-1 into the circulation in response to growth hormone (GH) stimulation (2, 3). Local tissues also secrete IGF-1 in response to GH, and this paracrine/autocrine IGF-1 acts together with the endocrine IGF-1 (mostly liver derived) to mediate the global growth promoting effects of GH (4). In addition to their role in regulating fetal, neonatal, and postnatal growth, IGFs are also involved in diverse processes including wound healing (5), development of CNS and other tissues (6), regulation of protein, carbohydrate, and lipid metabolism (7), neuroprotection (8), aging (9), etc. The diverse functions of this central hormonal pathway require that robust regulatory mechanisms be in place to avoid inappropriate regulation and/or dysfunction in different tissues and at different times. We now understand that IGF signaling is regulated by a family of specific IGF-binding proteins (IGFBPs) of which there are six distinct types in vertebrates. These IGFBPs share significant sequence homology and they are capable of binding IGFs with equal or greater affinity than the IGF1R. In fact, in both the circulation and in local tissues, most IGFs can be found bound to an IGFBP (10–13). In this review, we discuss the complex interplay of both overlapping and unique functions by which IGFBPs influence IGF signaling. THE IGFBP FAMILY The IGFBP family is evolutionarily ancient and highly conserved in vertebrates (11, 14–16). The six types of IGFBPs have been designated IGFBP-1 through IGFBP-6. Mammals generally possess one gene that belongs to each of the six types, and humans follow this pattern (Table 1). Some vertebrate species occasionally lack one or more of the types, and others have more than one IGFBP gene that can be classified within one type (Table 1). It is believed that the IGFBP family evolved via successive rounds of whole genome duplications. Notably, many teleost fish possess two copies of each of the six types of IGFBPs (Table 1), which is attributable to the third round of whole genome duplication that they are believed to have undergone following their divergence from the other vertebrates (16–21). Salmonid fish experienced an additional round of genome wide duplication and can have four copies of each IGFBP (22–24). We discuss the evolution of the IGFBP family in more detail in a later section. [Table: The IGFBP gene repertoire in selected vertebrate species.] All IGFBPs generally have approximately 200–300 amino acids and share a conserved structure consisting of a highly cysteine-rich N-terminal domain that is highly conserved among the IGFBP family and across species, a linker domain whose sequence is variable, and a cysteine-rich C-terminal domain that is also evolutionarily conserved (Figure 1A). The N- and C-terminal domains are globular and are structurally stabilized by multiple disulfide bonds between the conserved cysteine residues. Both of these domains participate in forming the IGF-binding site. The central linker domain is unstructured and serves to tether the N- and C-terminal domains together but also provides a location for functional motifs (10, 25). [Figure: (A) Domain structure of insulin-like growth factor-binding proteins (IGFBPs). IGFBPs contain conserved N- and C-terminal domains and a variable linker domain between them. The N-domain contains an insulin-like growth factor (IGF)-binding motif and the C-domain contains a thyroglobulin type-I repeat. The N-domain usually contains 12 conserved cysteine residues and the C-domain contains 6. (B) In extracellular environments, most IGFs are bound with IGFBPs, either in a binary complex containing one IGF and one IGFBP or a ternary complex consisting of an IGF, IGFBP-3 (or less often IGFBP-5), and a glycoprotein called acid labile subunit (ALS).] Many of the functions of different IGFBPs are made possible by their unique collection of functional motifs (Table 2). These functional motifs include binding sites for heparin, components of the extracellular matrix and cell surface proteoglycans; proteolytic cleavage sites; sites of post-translational modifications including glycosylation, etc. In addition, IGFBP-2, -3, -5, and -6 all contain functional nuclear localization sequences by which they are imported into the cell nucleus in certain cell types as we discuss below. [Table: Structural and biochemical characteristics of the six distinct types of IGFBPs.] It should be noted that a number of proteins belonging to the CCN (cyr61, ctgt, and Nov) protein family have been reported to contain sequences similar to the IGFBP N-domain and were once named IGFBP 7–12. It was later recognized that these were not IGFBPs and were renamed as IGFBP-related proteins and classified as part of a broader superfamily with the IGFBPs (26). The latter nomenclature has been questioned because these CCN family proteins not only lack high-affinity IGF-binding abilities but are also structurally no more related to IGFBPs than to von Willebrand factor, thrombospondin, or growth factor cysteine knots (27). These CCN family proteins will not be discussed in this review. IGFBP BIOLOGICAL ACTIONS In this section, we discuss a selection of

Read the complete text